Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care
|
|
- Virginia Watson
- 6 years ago
- Views:
Transcription
1 Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic 1
2 Outline Role of Molecular Profiling in the management of brain metastases Targeted/Immunotherapy in Management of brain metastases Management of brain metastases in the coming 3 5 years 2
3 Epidemiology of brain metastases Primary tumor Colon: 5% Melanoma: 9% Unknown primary: 11% Relative prevalence of brain metastases* Annual US incidence: >170K Ratio mets/primary: 10:1 All cancer patients: 15% 30% Autopsy incidence: 10% 30% Mean age: 60 years Median survival: 4 6 months Other known primary: 13% Breast: 15% Lung: 48% *Incidence increasing with better systemic Rx and improved survival 3 Courtesy: John Suh. Wen PY, et al. In: DeVita VT Jr, et al, eds. Cancer: Principles & Practice of Oncology. 2001:
4 Incidence of brain metastasis is increasing Incidence of brain metastasis is increasing 1 : Improvements in imaging (e.g. MRI) Clinical trial screening Improvements in systemic cancer control (brain is a sanctuary site) Rates of brain metastasis may be influenced by changing treatments 25% of lung cancer patients have brain metastasis at initial presentation 80% of lung cancer patients surviving >2 years will develop brain metastases MRI, magnetic resonance imaging. 4 Brain metastases may be underdiagnosed Autopsy results reveal brain metastases that were not diagnosed clinically 2 Clinical trial screening reveals patients with asymptomatic brain metastases 1 1. Ba JL et al. Oncology 2015; 29: ; 2. Ahluwalia MS, Winkler F. ASCO 2015:
5 Brain metastasis treatment: multidisciplinary strategy individualized for the patient 1 Goals of treatment: Control Macroscopic disease Microscopic disease Systemic disease Preserve Neurologic function Quality of life Treatment strategies: Corticosteroids WBRT Surgery +/- WBRT Surgery +/- localized radiation WBRT + radiation sensitizers WBRT + chemotherapy SRS +/- WBRT Chemotherapy Targeted therapy +/- WBRT Immunotherapy+/- SRS Factors used to assess therapy: Number of metastases Size of lesion(s) Location Neurological deficits Age/KPS Primary tumor/stage Extracranial disease Patient s input KPS, Karnofsky Performance Status; SRS, stereotactic radiosurgery; WBRT, whole-brain radiotherapy Ahluwalia MS, Winkler F. ASCO 2015:
6 Graded prognostic assessment tool for NSCLC BM Prognostic variables Scores for each factor Age Age > <50 KPS < ECM Present Absent Number of BM Number of BM > EM (+/-) KPS Median survival (months) by GPA 0 1 = = = = 14.8 EM, extracranial metastases; GPA, graded prognostic assessment; NSCLC, non-small-cell lung cancer. 6 Balasubramanian SK et al. J Clin Oncol 2016; 34 (suppl): abstr 2005; Sperduto PW, et al. Int J Radiat Oncol Biol Phys. 2010;77(3):
7 Impact of EGFR and ALK mutation on the Outcomes of Non-small cell Lung cancer (NSCLC) Patients with Brain Metastases NSCLC Patient Characteristics Factors Mutation+ (M+) Wild Type (WT) (N=91) (N=257) P-value Age 60.0(29.8,82.6) 60.8(37.3,92.8) KPS 0.90 < 70 9 (10.2) 28 (11.9) (39.8) 109 (46.2) > (50.0) 99 (41.9) Brain Mets 2.0(1.00,99.0) 2.0(1.00,99.0) (37.4) 118 (46.5) (26.4) 70 (27.6) > 3 33 (36.3) 66 (26.0) Symptomatic Asymptomatic 33 (37.1) 68 (27.6) Symptomatic 56 (62.9) 178 (72.4) Synchronous No 39 (42.9) 97 (37.7) <0.001 Yes 52 (57.1) 160 (62.3) Extracranial Metastases (ECM) No 26 (28.6) 104 (40.6) Yes 65 (71.4) 152 (59.4) 7 Balasubramanian SK et al. J Clin Oncol 2016; 34 (suppl): abstr 2005
8 Multivariate analysis without ECM Mutation + HR (95%CI ) Overall survival P-value Wild type HR (95%CI ) Age ( <50 vs vs >60) 1.28 (0.88, 1.86) (0.84, 1.33) 0.65 KPS (<70 vs vs >80) 0.35 (0.22, 0.55) < (0.56, 0.89) Brain mets (1 vs 2 3 vs >3) 0.95 (0.69, 1.31) (1.08, 1.59) Symptomatic 0.87 (0.48, 1.60) (0.67, 1.40) 0.85 Synchronous 0.69 (0.40, 1.19) (0.60, 1.15) 0.25 P-value 8 Balasubramanian SK et al. J Clin Oncol 2016; 34 (suppl): abstr 2005
9 Multivariate analysis including ECM Mutation+ HR (95% CI) Overall survival P-value Wild type HR (95% CI) Age ( <50 vs vs >60) 1.28 (0.88, 1.88) (0.84, 1.34) 0.62 KPS (<70 vs vs >80) 0.35 (0.22, 0.55) < (0.54, 0.87) Brain mets (1 vs 2 3 vs >3) 0.95 (0.69, 1.31) (0.99, 1.46) Symptomatic 0.87 (0.48, 1.60) (0.75, 1.59) 0.65 Synchronous 0.69 (0.40, 1.18) (0.58, 1.11) 0.18 ECM (yes / no) 0.97 (0.54, 1.74) (1.37, 2.77) <0.001 P-value 9 Balasubramanian SK et al. J Clin Oncol 2016; 34 (suppl): abstr 2005
10 The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in 1521 Patients With Adenocarcinoma of the Lung and Brain Metastases Proportion surviving ALK positive (n=86, MST=45) EGFR positive (n=235, MST=23) KRAS positive (n=211, MST=12) EGFR & ALK neg (n=284, MST=14) Unknown (n=705, MST=12) Months from start of BM treatment 10 Sperduto P et al. Int J Radiat Oncol Biol Phys Oct 1;96(2):
11 Management of brain metastases in TKI-naïve EGFR mutationpositive NSCLC: retrospective analysis 351 EGFR-mutant NSCLC BM from six institutions SRS followed by EGFR-TKI (n=100) WBRT followed by EGFR-TKI (n=120) EGFR-TKI followed by SRS or WBRT at progression (n=131) OS and IC-PFS were measured from the date of brain metastases EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; IC-PFS, intracranial progression-free survival. 11 Magnuson WJ, et al. J Clin Oncol. 2017;35(10):
12 Management of brain metastases in TKI-naïve EGFR mutationpositive NSCLC: overall survival The median OS for the SRS, WBRT, and EGFR-TKI cohorts was 46, 30, and 25 months respectively (p<0.001) 12 Magnuson WJ, et al. J Clin Oncol. 2017;35(10):
13 EGFR inhibitors and RT Study Design Combination Number of patients Intracranial PFS (months) OS (Months) Welsh, et al. Phase II Erlotinib + WBRT Lee, et al. Phase II Arm A: WBRT Arm A: Arm B: WBRT + erlotinib Arm B: RTOG-0320 Phase III Arm A: WBRT + SRS Arm A: Arm B: WBRT + SRS + TMZ Arm B: Arm C: WBRT +SRS + erlotinib Arm C: Zhou, et al. Phase I Icotinib + WBRT NR 13 Sperduto PW, et al. Int J Radiat Oncol Biol Phys. 2013;85(5): ; Welsh JW, et al. J Clin Oncol. 2013;31: ; Zhou L, et al. Lung Cancer. 2016;96:
14 ALK inhibitors and BM ALK inhibitor Study design Number of patients Crizotinib Ceritinib Post-hoc analysis of PROFILE-1005 and 1007 Post-hoc analysis of ASCEND-1 Loco-regional control (ORR) 22 18% 18 33% 98 ( ALK pretreated) 50% 26 (ALK naïve) 69% Alectinib Phase I/II study 34 56% Brigatinib Phase II study 13 69% 14 Costa DB, et al. J Clin Oncol. 2015;33(17): Shaw E, et al. Neuro-Oncology. 2014;16(suppl 5):v39; Gadgeel SM, et al. Lancet Oncol. 2014;15(10): ; Kerstein D, et al. Ann Oncol. 2015;26(suppl1):i60-i61.
15 Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive NSCLC 15 Gadgeel SM, et al. J Clin Oncol. 2016;34(34):
16 Phase II trial of pembrolizumab for untreated brain metastases Key eligibility: Advanced NSCLC or melanoma At least one untreated or progressive brain metastasis 5 20 mm No neurologic symptoms or steroid requirement PS 0 1 PD-L1 expression from tumor biopsy after most recent systemic therapy Pembrolizumab 10 mg/kg q2w Brain metastasis PD Brain metastasis CR, PR, or SD Consider radiation or surgery to progressing lesions Continue pembrolizumab if systemic control achieved Safety evaluation at 4 weeks: Brain MRI Response evaluation every 8 weeks: Brain MRI CT chest/abdomen/pelvis Primary endpoint: brain metastasis response rate Secondary endpoints: overall response rate, safety, PFS, OS CT, computed tomography; PD-L-1, programmed cell death ligand-1; PS, performance status; q2w, every 2 weeks; SD, standard deviation. 16 Courtesy: Harriet Kluger.
17 Best brain metastasis response by mrecist Note: 4 patients were unevaluable in the brain due to rapid systemic progression 17 Courtesy: Sarah Goldberg.
18 CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two Phase II trials The CNS ORR was 54% (95% CI 39, 68) Median best percentage change from baseline in CNS target lesion size was -53% (range: -100% +80%) Best change from baseline in target lesion size (%) 100 * Complete response Partial response Stable response Progressive response Not evaluable Patients evaluable for CNS response (n=50) CNS ORR*, % Complete response, n (%) Partial response, n (%) Stable disease 6 weeks, n (%) Progressive disease, n (%) Not evaluable, n (%) 54 (95% CI 39, 68) 6 (12) 21 (42) 19 (38) 3 (6) 1 (2) CNS DCR, % 92 (95% CI 81, 98) CNS response based on prior brain RT status* Prior RT 6 months before first dose, n 19 / 50 CNS ORR, % Complete response / partial response, % 32 (95% CI 13, 57) 11 / 21 No prior RT or RT >6 months before first dose, n 31 / 50 CNS ORR, % Complete response / partial response, % 68 (95% CI 48, 83) 13 / 55 Population: evaluable for response. Scans were performed every 6 weeks *represents imputed values CI, confidence interval 18 Goss G et al. Presented at WCLC 2016 J Thorac Oncol 2017; 12(suppl):S440-S441 (abstr MA16.11)
19 PFS benefit in AURA3 patients with CNS metastases at baseline With CNS metastases Without CNS metastases 1.0 Median PFS, months (95% CI) Osimertinib (n=93) 8.5 (6.8, 12.3) Platinum-pemetrexed (n=51) 4.2 (4.1, 5.4) 1.0 Median PFS, months (95% CI) Osimertinib (n=186) 10.8 (8.3, 12.5) Platinum-pemetrexed (n=89) 5.6 (4.2, 6.8) Probability of progression-free survival HR 0.32 (95% CI 0.21, 0.49) Probability of progression-free survival HR 0.40 (95% CI 0.29, 0.55) No. at risk Osimertinib Platinumpemetrexed Months Months Papadimitrakopoulou V et al. Presented at WCLC 2016 (J Thorac Oncol 2017; 12(suppl): S5-S6 (abstr PL03.03) Mok TS et al. NEJM 2017; 376:
20 Breast Cancer BM 10-30% of breast cancer develop BM HER2 positive: 30-55% chance of BM HER2 positive: Trastuzumab, Lapatinib, Neratinib, trastuzumab-emtansine (T-DM1), pertuzumab Triple negative : 25-45% chance of BM Triple negative: may be amenable to targeted therapy PARP inhibitor Lim E, Lin NU. Oncology (Williston Park).2014 Jul;28(7):
21 Targeted therapy Before and After WBRT Lapatinib/capecitabine N Response rate*(%) Progression after WBRT Before WBRT * 50% volumetric reduction of CNS lesions 1 Lin, Clin Cancer Res, Batchelot, Lancet Oncology
22 Ongoing trials in BCBM Study Design Targeted therapy Local therapy Estimated enrollment NCT NCT NCT NCT Phase 2, randomized, multicenter Phase 2, open label, multicenter Phase 2, open label, multicenter Phase 1, open label, single center Lapatinib WBRT/SRS 143 Neratinib and capecitabine None 105 Cabazitaxel and lapatinib None 11 T-DM1 WBRT 36 NCT Phase 2, randomized, double blinded, multicenter ONT-380 vs placebo Plus capecitabine and trastuzumab None 180 NCT Phase 2, open label, single center Everolimus+ trastuzumab + vinorelbine None 35 NCT Phase 1b/2, open label, single center Lapatinib+ Everolimus + Capecitabine None 47 22
23 Melanoma BM Up to 40% of melanoma pts BM MBM: median survival is 6 months CTLA4 MoAb: Ipilimumab BRAF - : Vemurafenib, Dabrafenib MEK - : Trematinib, Cobimetinib Anti PD1: Pembrolizumab, Nivolumab 23
24 Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial Margolin K. Lancet Oncol May;13(5):
25 Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial Disease control 12 /51 in cohort A (24%) 2/21 cohort B (10%) Margolin K. Lancet Oncol May;13(5):
26 Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial Disease control 12 /51 in cohort A (24%) 2/21 cohort B (10%) Margolin K. Lancet Oncol May;13(5):
27 Phase II Trial of Pembrolizumab for Untreated Brain Metastases Key Eligibility: Advanced NSCLC or melanoma At least 1 untreated or progressive brain metastasis 5-20mm No neurologic symptoms or steroid requirement PS 0-1 PD-L1 expression from tumor biopsy after most recent systemic therapy Pembrolizumab 10mg/kg q2 weeks Brain metastasis PD Brain metastasis CR, PR, or SD Consider radiation or surgery to progressing lesions Continue pembrolizumab if systemic control achieved Safety evaluation at 4 weeks: Brain MRI Response evaluation every 8 weeks: Brain MRI CT chest/abdomen/pelvis Primary Endpoint: Brain Metastasis Response Rate Secondary Endpoints: Overall response rate, safety, PFS, OS 27 Courtesy: Harriet Kluger
28 Safety and activity of Pembrolizumab in melanoma patients with untreated brain metastases Baseline A B C D After 1 dose, Headaches E F Courtesy: Harriet Kluger 28 G H
29 Future directions: takeaway points Control Macroscopic disease: SRS, WBRT? Number Targeted/immune therapy (radiation sensitizers?) Microscopic disease: targeted/immune therapy Systemic disease: targeted/immune therapy Preserve Neurologic function: primary endpoint in clinical trials, appropriate tests, time point Selection of therapy for BM: multidisciplinary approach Clinical trials are critical to define care in BM 29
Overview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationAlleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen?
Department of Radiation Oncology Chairman: Prof. Dr. Matthias Guckenberger Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen? Matthias
More informationBRAIN METS IN 2018: ANY CLOSER TO THE END OF A LONG AND WINDING ROAD?
BRAIN METS IN 2018: ANY CLOSER TO THE END OF A LONG AND WINDING ROAD? M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Molecular targets in primary cancers
More informationBrain metastases and meningitis carcinomatosa: Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland
Brain metastases and meningitis carcinomatosa: a palliative situation? Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland SAMO, Lucerne, February 1-2, 2013 Treatment options for NSCLC patients
More informationSociety for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases
Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Geoffrey T. Gibney, MD Georgetown-Lombardi Comprehensive Cancer Center Medstar-Georgetown University Hospital
More informationTargeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont. Masterclass 27 september 2018
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont Masterclass 27 september 2018 Outline Introduction EGFR TKI ALK TKI TKI for uncommon driver mutations Take home messages The promise of
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationRecent Advances in Lung Cancer: Updates from ASCO 2017
Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017
More informationBrain metastases: future developments. Emilie Le Rhun Lille, France
Brain metastases: future developments Emilie Le Rhun Lille, France Disclosures ELR has received research grants from Mundipharma and Amgen and honoraria for lectures or advisory board participation from
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationBrain mets under I.O.
Brain mets under I.O. Bernard Escudier Gustave Roussy, Villejuif, France Disclosure Honorarium received from BMS, Novartis, Pfizer, Bayer, Roche, Exelixis, Ipsen, Eisai, Calithera Travel Grant from BMS,
More informationImpact of Targeted/Immunotherapy on Gamma Knife Radiosurgery
Impact of Targeted/Immunotherapy on Gamma Knife Radiosurgery Veronica Chiang, MD Yale University Department of Neurosurgery IGKRF Scientific Session University of Pennsylvania, Philadelphia June 23-24,
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationOpzioni terapeutiche nel paziente ALK-traslocato
Opzioni terapeutiche nel paziente ALK-traslocato Giulio Metro S.C. Oncologia Medica Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia Carcinoma del polmone non microcitoma: quali
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationOptimal Management of Isolated HER2+ve Brain Metastases
Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not
More informationStereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms. Overall Clinical Significance 8/3/13
Stereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms Jason Sheehan, MD, PhD Departments of Neurosurgery and Radiation Oncology University of Virginia, Charlottesville, VA USA Overall
More informationCombined treatment of Brain metastases: Radiosurgery and Targeted therapy
Combined treatment of Brain metastases: Radiosurgery and Targeted therapy Stephanie Kroeze, MD PhD OVERVIEW Introduction brain metastases Targeted therapy as monotherapy Efficacy of SRS combined with Targeted
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationTargeted Therapies and Immunotherapies For Brain Metastases
Targeted Therapies and Immunotherapies For Brain Metastases Patrick Y. Wen, M.D. Center For Neuro-Oncology Dana Farber/Brigham and Women s Cancer Center Division of Neuro-Oncology, Department of Neurology
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationNCCN Guidelines for Central Nervous System Cancers V Follow-Up on 02/23/18
GLIO-3 and GLIO-4 Submission from Novocure Inc. (12/19/17 and 9/7/17) Please consider adding tumor treating fields in combination with temozolomide for the treatment of adult patients with newly diagnosed,
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationCerebel trial Any impact on the clinical practice? Antonio Frassoldati Oncologia Clinica - Ferrara
Cerebel trial Any impact on the clinical practice? Antonio Frassoldati Oncologia Clinica - Ferrara CNS metastases in HER2+ BC The proportion of patients with HER2+ advanced breast cancer who have CNS metastases
More informationIntracranial efficacy of crizotinib versus chemotherapy in PROFILE 1014: shining a light on central nervous system endpoints in clinical trials
Perspective Intracranial efficacy of crizotinib versus chemotherapy in PROFILE 1014: shining a light on central nervous system endpoints in clinical trials Terry L. Ng, D. Ross Camidge Division of Medical
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationLung Cancer Update 2016 BAONS Oncology Care Update
Lung Cancer Update 2016 BAONS Oncology Care Update Matthew Gubens, MD, MS Assistant Professor Chair, Thoracic Oncology Site Committee UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Consulting
More informationLe#eratura ed esperienza clinica piemontese C. Mantovani (Torino)
RADIOCHIRURGIA E RADIOTERAPIA STEREOTASSICA INTRACRANICA: ESPERIENZE CLINICHE E INTEGRAZIONI CON TERAPIE SISTEMICHE Le#eratura ed esperienza clinica piemontese C. Mantovani (Torino) RADIOCHIRURGIA E RADIOTERAPIA
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Management of Brain Metastases Dr. Luis Souhami Professor Department of Radiation Oncology University,
More informationEfficacy of anti-pd-1 therapy in patients with melanoma brain metastases
Efficacy of anti-pd-1 therapy in patients with melanoma brain metastases John J. Park 1, Sagun Parakh 2,3,4, Shehara Mendis 5, Rajat Rai 6, Wen Xu 7, Serigne Lo 6, Martin Drummond 6, Catherine Rowe 7,
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationD Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationMinesh Mehta, Northwestern University. Chicago, IL
* Minesh Mehta, Northwestern University Chicago, IL Consultant: Adnexus, Bayer, Merck, Tomotherapy Stock Options: Colby, Pharmacyclics, Procertus, Stemina, Tomotherapy Board of Directors: Pharmacyclics
More informationImmunotherapy for the Treatment of Brain Metastases
Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Lawrence G. Lum, MD, DSc Karmanos Cancer Institute and Wayne State University Advances in Cancer Immunotherapy
More informationTargeted Cancer Therapies
Targeted Cancer Therapies Primary Care Training Programme 14 th February 2018 Sin Chong Lau Consultant in Medical Oncology Financial Disclosure Honoraria: Amgen, Pfizer, Roche, Sanofi, Servier Meetings:
More informationRadiotherapy and Brain Metastases. Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem
Radiotherapy and Brain Metastases Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem 24-02-2017 Possible strategies Watchful waiting Surgery Postop RT to resection cavity or WBRT postop SRS
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationOptimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More informationOTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento
OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento Dolores Isla Servicio de Oncología Médica HCU Lozano Besa de Zaragoza 2008 Selection Factors in Advanced NSCLC ( 8y ago)
More informationEGFR Mutation-Positive Acquired Resistance: Dominance of T790M
Treatment of EGFR Mutation-Positive Acquired Resistance: T790M+ or T790M- H. Jack West, MD Swedish Cancer Institute, Seattle, WA EGFR Mutation-Positive Acquired Resistance: Dominance of T790M Yu, Clin
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationSpecial Situation: Brain metastases
ESMO Advanced Course on Unsolved Questions in Immuno-Oncology February 16-17 2018, Amsterdam, Netherlands Special Situation: Brain metastases Matthias Preusser, MD Associate Professor of Medicine Department
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationTargeted Therapy for NSCLC: EGFR and ALK Fadlo R. Khuri, MD
EGFR and ALK Fadlo R. Khuri, MD President, American University of Beirut Professor of Medicine July 26, 2018 A great year end! Targeted Therapy for NSCLC: Evolving Landscape of Lung Adenocarcinoma NSCLC
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationNCCN Non Small Cell Lung Cancer V Meeting July 8, 2016
NSCL 3 Submission from Myriad requesting the following statement to be listed as an additional high risk factor in footnote p : For lung ADC, a highrisk 46 gene molecular prognostic score determined by
More informationALK positive Lung Cancer. Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan
ALK positive Lung Cancer Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan Objectives What is ALK translocation? What drugs are used in what sequence? How many times
More informationDr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More information14,30 18,20. II Sessione. Moderatori: Giovanni Apolone, Roberto Labianca
14,30 18,20 II Sessione Moderatori: Giovanni Apolone, Roberto Labianca 15,10 15,30 Ca polmonare (never smokers): attualità e prospettive di ricerca Giulio Metro Ca polmonare (never smokers): attualità
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationRecent Advances in Lung Cancer: Updates from ASCO 2016
Recent Advances in Lung Cancer: Updates from ASCO 2016 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/23/2016
More informationSequencing in EGFR-Mutated NSCLC: Does Order Matter?
Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationNew options for old and new targets in NSCLC Rosario García Campelo Medical Oncology Unit University Hospital A Coruña
New options for old and new targets in NSCLC Rosario García Campelo Medical Oncology Unit University Hospital A Coruña Phase II GOAL TRIAL DESIGN Key inclusion criteria Patients with locally advanced or
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationTreatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC
Treatment and management of advanced melanoma: 2018 Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Disclosure Paul B. Chapman, MD Nothing to disclose. Off
More informationWHAT S HOT IN MELANOMA CNS METASTASES?
WHAT S HOT IN MELANOMA CNS METASTASES? GIUSEPPE MINNITI, MD, PHD Radiation Unit, UPMC, Hillman Cancer Center, San Pietro Hospital, Rome, and IRCCS Neuromed, Pozzilli (IS), Italy Marseille, September 21-22,
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationTargeted therapy with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer even with brain metastasis
JBUON 2017; 22(3): 586-591 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com REVIEW ARTICLE Targeted therapy with anaplastic lymphoma kinase inhibitors in non-small
More informationUpdates in the management of brain (leptomeningeal) metastasis of lung cancer
Oncology and Translational Medicine DOI 10.1007/s10330-018-0274-4 August 2018, Vol. 4, No. 4, P144 P150 REVIEW ARTICLE Updates in the management of brain (leptomeningeal) metastasis of lung cancer Ziyi
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationCorporate Medical Policy
Corporate Medical Policy Proteomic Testing for Targeted Therapy in Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteomic_testing_for_targeted_therapy_in_non_small_cell_lung_cancer
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationSupplementary Online Content
Supplementary Online Content Mezquita L, Auclin E, Ferrara R, et al. Association of the Lung Immune Prognostic Index with immune checkpoint inhibitor outcomes in patients with advanced non small cell lung
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationThe oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC
The oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC Egbert F. Smit Department of Thoracic Oncology, Netherlands Cancer Institute, and Department
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationProtocolos de consenso: MTS Cerebrales Resumen ASTRO. Javier Aristu y Germán Valtueña Servicio Oncología Rad. Depart.
Protocolos de consenso: MTS Cerebrales Resumen ASTRO Javier Aristu y Germán Valtueña Servicio Oncología Rad. Depart. ASTRO 2013 Brain met SRS Abstracts 97. Comparative Effectiveness of SRS versus WBRT
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More information